title: Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations.
abstract: To characterize altered alveolar transfer to solute in bleomycin (BLM)-injured lungs, eight dogs underwent a gadolinium diethylenetriaminepentaacetic acid aerosol (Gd-AS) magnetic resonance imaging study before and on Days 7 and 40 after tracheal instillation of BLM (0.75 mg) in the left lungs. Consecutive fast-gradient echo magnetic resonance imaging was acquired during and after spontaneous inhalation of 200-mM Gd-AS. The slope (Kep) and clearance half-time (T1/2) of logarithmic regression lines for clearance curves were estimated. Histology on Day 40 was compared with that on Day 7 in another three dogs. On Days 7 and 40, Gd-AS deposition was heterogeneously reduced in the affected lungs. On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001). However, on Day 40 with multifocal interstitial fibrosis, Kep and T1/2 were recovered toward baseline. BLM-injured lungs can be characterized by accelerated Gd-AS clearance during the acute exudative phase and their recovery during the chronic fibrotic phase. This technique is acceptable for monitoring alveolar transfer changes in BLM-injured lungs.
authors.affiliation: Department of Radiology, Yamaguchi University School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan. sugar@po.cc.yamaguchi-u.ac.jp
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Suga
authors.forename: Yue
authors.initials: Y
authors.lastname: Yuan
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Ogasawara
authors.forename: Toshinobu
authors.initials: T
authors.lastname: Tsukuda
authors.forename: Naofumi
authors.initials: N
authors.lastname: Matsunaga
mesh_terms: D000208:Acute Disease; D000280:Administration, Inhalation; D000336:Aerosols; D000818:Animals; D001761:Bleomycin; D002908:Chronic Disease; D003287:Contrast Media / Q000008:administration & dosage / Q000378:metabolism*; D004195:Disease Models, Animal; D004285:Dogs; D019786:Gadolinium DTPA / Q000008:administration & dosage / Q000378:metabolism*; D007322:Instillation, Drug; D016014:Linear Models; D008279:Magnetic Resonance Imaging / Q000379:methods; D008657:Metabolic Clearance Rate; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism*; D012720:Severity of Illness Index; D013997:Time Factors; D014132:Trachea
chemical_list: D000336:Aerosols; D003287:Contrast Media; D001761:Bleomycin; D019786:Gadolinium DTPA